A Quality By Design Approach For Longitudinal Quality Attributes

References

• Box, G. E. P., Tiao, G. C. (1973). Bayesian Inference in Statistical Analysis. New York, NY: Wiley Classic Library.
   Google Scholar
• Chib, S., Carlin, B. P. (1999). On MCMC sampling in hierarchical longitudinal models. Statistics and Computing. 9:17–26.
   Web of Science ®Google Scholar
• Deming, W. E. (1986). Out of the Crisis. Cambridge, MA: Massachusetts Institute of Technology Center for Advanced Engineering Study.
   Google Scholar
• Guttman, I. (1970). Statistical Tolerance Regions: Classical and Bayesian. Griffin’s statistical monographs and courses. London: Griffin.
   Google Scholar
• Hamada, M., Johnson, V., Moore, L. M. (2004). Bayesian prediction intervals and their relationship to tolerance intervals. Technometrics 46:452–459.
   Web of Science ®Google Scholar
• ICH-Q2R Guideline. (2005). International Conference on Harmonization (ICH) of Technical Requirements for registration of Pharmaceuticals for Human Use, Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology, Geneva, 2005.
   Google Scholar
• ICH Q8. (2009). International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q8 (R2): Pharmaceutical Development, Geneva.
   Google Scholar
• ICH Q9. (2005). International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q9: Quality Risk Management, Geneva.
   Google Scholar
• ICH Q10. (2008). International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q10: Pharmaceutical Quality System, Geneva.
   Google Scholar
• Juran, J. M. (1951). Quality Control Handbook, 1st ed. New York: McGraw-Hill.
   Google Scholar
• Lebrun, P., Boulanger, B., Debrus, B., Lambert, P., Hubert, P. (2013). A Bayesian design space for analytical methods based on multivariate models and predictions. Journal of Biopharmaceutical Statistics. 23:186–198.
   Web of Science ®Google Scholar
• Miró-Quesada, G., del Castillo, E., Peterson, J. J. (2004). A Bayesian approach for multiple response surface optimization in the presence of noise variable. Journal of Applied Statistics 13:251–270.
   Web of Science ®Google Scholar
• Peterson, J. J. (2004). A posterior predictive approach to multiple response surface optimization. Journal Quality Technology 36:139–153.
   Web of Science ®Google Scholar
• Peterson, J. J. (2008). A Bayesian approach to the ICH Q8 definition of design Space. Journal Biopharmaceutical Statistics 18:959–975.
   PubMed Web of Science ®Google Scholar
• Peterson, J. J., Lief, K. (2010). The ICH Q8 definition of design space: A comparison of the overlapping means and the Bayesian predictive approaches. Statistics in Biopharmaceutical Research 2:249–259.
   Google Scholar
• Peterson, J. J., Miró-Quesada, G., del Castillo, E. (2009). A Bayesian reliability approach to multiple response optimization with seemingly unrelated regression models. Journal of Quality Technology Quantitative Management 6:353–369.
   Web of Science ®Google Scholar
• Peterson, J. J., Yahyah, M. (2009). A Bayesian design space approach to robustness and system suitability for pharmaceutical assays and other processes. Statistics in Biopharmaceutical Research 1:441–449.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). (1997a). Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. August 1997.
   Google Scholar
• U.S. Food and Drug Administration (FDA). (1997b). Guidance for Industry: SUPAC-MR. Modified Release Solid Oral Dosage Forms. September 1997.
   Google Scholar
• U.S. Food and Drug Administration (FDA). (2007). Department of Health and Human Services, Pharmaceutical Quality for the 21st Century A Risk-Based Approach Progress Report, May 2007.
   Google Scholar
• U.S. Food and Drug Administration (FDA). (2011a). Applying ICH Q8(R2), Q9, and Q10 principles to CMC review. Chapter 5000 – Pharmaceutical Sciences, MAPP 5016.1, February 2011.
   Google Scholar
• U.S. Food and Drug Administration (FDA). (2011b). Department of Health and Human Services, Guidance for industry; Process Validation: General Principles and Practices, January 2011.
   Google Scholar
• USP 32-NF 27 (2009). Chapter <711> Dissolution, August 2009.
   Google Scholar
• Vaghela, B., Kayastha, R., Bhatt, N., Pathak, N., Rathod, D. (2011). Development and validation of dissolution procedures. Journal of Applied Pharmaceutical Science 01:50–56.
   Google Scholar
• Yu, L. (2008). Pharmaceutical quality by design: product and process development, understanding, and control. Pharmaceutical Research, 25:781–791.
   PubMed Web of Science ®Google Scholar